Most people take Xarelto for at least 3 months to treat a deep vein thrombosis, but the total duration depends on what caused the clot and your risk of it happening again. Some people stay on it for 6 months, and others take it indefinitely. The key factor is whether your DVT was “provoked” by a temporary trigger or appeared without an obvious cause.
The Two-Phase Dosing Schedule
Xarelto treatment starts with a higher loading dose. For the first 21 days, the FDA-approved regimen is 15 mg taken twice daily with food. After that initial three-week period, the dose drops to 20 mg once daily with food, taken at roughly the same time each day. This front-loaded approach delivers more aggressive clot treatment during the critical early weeks when the clot is fresh and most dangerous.
Taking Xarelto with food matters for absorption. Missing doses or taking them on an empty stomach can reduce the drug’s effectiveness, which is especially important during those first 21 days.
3 Months for Provoked DVT
If your DVT was triggered by a temporary, identifiable risk factor, the standard recommendation is 3 months of anticoagulation, then stopping. The American College of Chest Physicians has recommended this 3-month cutoff for provoked DVT since at least 2008, and it remains the current guideline.
Triggers that qualify a clot as “provoked” include recent surgery, a broken bone or cast that immobilized a limb, childbirth, and oral contraceptive use. The logic is straightforward: once the temporary trigger is gone, your baseline clot risk returns to normal, and the bleeding risks of continued blood thinners outweigh the benefits. At the 3-month mark, guidelines recommend discontinuing anticoagulation entirely for these patients, assuming no other reason to stay on it.
6 Months or Longer for Unprovoked DVT
When a DVT appears without a clear trigger, the picture changes significantly. Unprovoked clots carry a much higher risk of coming back after you stop treatment. A large meta-analysis published in The BMJ found that in the first year after stopping anticoagulation for a first unprovoked clot, roughly 10 out of every 100 patients developed another clot. That’s a substantial recurrence rate.
Because of this risk, current guidelines suggest that people with unprovoked DVT should consider extended anticoagulation of indefinite duration, unless they have a high risk of bleeding complications. “Indefinite” doesn’t necessarily mean forever. It means there’s no predetermined stop date. Instead, your doctor reassesses periodically whether the benefit of preventing another clot still outweighs the bleeding risk.
The decision isn’t always clear-cut. Several scoring tools exist to help estimate both your recurrence risk and your bleeding risk, but none of them are precise enough to make the call on their own. Clinicians use these tools alongside a broader assessment of your overall health, preferences, and comfort level with staying on a blood thinner long term.
DVT With Active Cancer
Cancer-associated blood clots follow a different timeline. The American Society of Hematology recommends long-term anticoagulation (beyond 6 months) for patients with active cancer and DVT, rather than the standard 3 to 6 month course. For many cancer patients, the recommendation is to continue anticoagulation indefinitely rather than stopping after a set period.
“Active cancer” in this context means a non-skin cancer diagnosed within the past 6 months, cancer treated within the past 6 months, or cancer that is recurrent or metastatic. Long-term anticoagulation can be discontinued when the cancer is in sustained remission and the patient is no longer considered high risk for another clot.
The Low-Dose Option for Extended Treatment
If you and your doctor decide on extended treatment beyond the initial course, there’s a lower-dose option. A major clinical trial called EINSTEIN-CHOICE compared three approaches in patients who had completed their initial DVT treatment: Xarelto 20 mg daily, Xarelto 10 mg daily, and aspirin.
Both Xarelto doses dramatically outperformed aspirin. The recurrence rate was 0.6% with the 10 mg dose and 0.8% with the 20 mg dose, compared to 2.6% with aspirin alone. The critical finding was that the lower 10 mg dose worked just as well as the full 20 mg dose at preventing new clots, with slightly less bleeding risk. Major bleeding occurred in 0.4% of patients on the 10 mg dose versus 0.5% on the 20 mg dose. This gives patients who need long-term protection an option that’s effective with a more favorable safety profile.
What Influences Your Specific Timeline
Several factors push the duration shorter or longer. A first-time DVT provoked by a major, one-time event like surgery is the most straightforward: 3 months, then stop. A first unprovoked DVT lands in the gray zone where you and your doctor weigh recurrence against bleeding. A second unprovoked DVT almost always tips the balance toward indefinite treatment, because recurrence risk is substantially higher after a second event.
Minor transient risk factors, like a long flight or a short illness that kept you in bed, fall into a middle category. These “minimally provoked” clots carry more recurrence risk than those triggered by surgery but less than truly unprovoked ones. Current European guidelines suggest that even a DVT linked to a minor transient trigger may warrant extended anticoagulation.
Persistent risk factors also matter. Conditions like autoimmune disorders, obesity, or clotting disorders that don’t go away mean your elevated risk doesn’t go away either. For these patients, extended treatment is typically recommended as long as bleeding risk remains acceptable.
Bleeding risk itself is the main counterweight. Factors that raise your bleeding risk include uncontrolled high blood pressure, regular use of anti-inflammatory painkillers, older age, kidney problems, and a history of bleeding events. When bleeding risk is high, doctors focus on correcting whatever modifiable factors they can, such as better blood pressure control and avoiding unnecessary anti-inflammatory medications, to make continued anticoagulation safer.